Insulin Glargine Pharmacokinetics and Clinical Implications

Introduction to Insulin Glargine

• Insulin glargine has no pronounced peak action time, providing a relatively constant concentration profile over 24 hours, which distinguishes it from intermediate-acting insulins and makes it an ideal basal insulin, as noted by the American Academy of Family Physicians 1, 2, 3

Pharmacokinetic Profile

• Insulin glargine has an onset of action of approximately 1 hour after subcutaneous injection, with a duration of action of approximately 24 hours, allowing for once-daily dosing, according to the American Academy of Family Physicians 1, 3
• Insulin glargine slowly releases insulin over 24 hours, causing more physiologic basal insulin levels, as reported by the American Academy of Family Physicians 4

Clinical Implications

• The absence of a peak action time reduces the risk of hypoglycemia compared to intermediate-acting insulins, as found by the American Academy of Family Physicians 1, 2, 3
• The peakless profile allows for more stable blood glucose levels between meals and overnight, as noted by the American Academy of Family Physicians 3, 4

Comparison with Other Insulins

• The following table compares insulin glargine to other insulin types:

Administration Considerations

• Insulin glargine is typically administered once daily, often at bedtime, though it can be given at any time of day with similar efficacy, according to the American Diabetes Association, as reported in Diabetes Care 5

Administration Timing of Insulin Glargine

Clinical Considerations for Timing Decision

• The American Diabetes Association recommends changing the timing of insulin glargine administration from bedtime to morning when simplifying insulin regimens for older adults 6

Basal Insulin Therapy with Insulin Glargine

Clinical Applications and Administration

• The American Diabetes Association recommends insulin glargine as basal insulin therapy, primarily restraining hepatic glucose production and limiting hyperglycemia overnight and between meals 7
• In type 1 diabetes, insulin glargine should be used in combination with short-acting insulin analogs to cover prandial insulin needs, as suggested by the American Diabetes Association 8
• Starting doses of insulin glargine can be estimated based on body weight (0.1–0.2 units/kg/day) and the degree of hyperglycemia, with individualized titration over days to weeks, according to the American Diabetes Association 7

Clinical Advantages

• Insulin glargine has demonstrated a lower risk of symptomatic and nocturnal hypoglycemia compared to NPH insulin, as reported by the American Diabetes Association 7
• Insulin glargine belongs to the same class as other long-acting insulin analogs such as detemir and degludec, all designed to provide basal insulin coverage, as classified by the American Diabetes Association 7